On August 5th, Guoao-Hill Associates reported that China Securities Co., Ltd. research reports pointed out that China Resources Sanjiu Medical & Pharmaceutical (000999.SZ) plans to purchase a total of 28% of Tasly Pharmaceutical Group held by Tasly Pharmaceutical Group and its concerted action parties in cash. After the completion of this transaction, Tasly Pharmaceutical Group's controlling shareholder will change from Tasly Pharmaceutical Group to China Resources Sanjiu Medical & Pharmaceutical. It is believed that the company is a rare multi-brand successful operation platform in the self-diagnosis and treatment field, while Tasly Pharmaceutical Group is a modern Chinese medicine prescription drug leading enterprise focusing on the three major disease areas of cardiovascular and cerebrovascular, digestive and metabolic, and tumor. This acquisition is conducive to China Resources Sanjiu Medical & Pharmaceutical consolidating its leading position in the industry, enhancing its core competitiveness, realizing complementary, strong, and extended links in the traditional Chinese medicine industry chain by fully integrating the resources of both parties, exerting research and development synergy value, and enhancing its innovation and development capabilities. The long-term growth potential is expected to accelerate. Maintaining a "buy" rating.